SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is generating significant buzz from its CES keynote, where CEO Lisa Su is highlighting groundbreaking advancements like the MI500 series promising 1000x AI performance by 2027 and new Ryzen AI processors for various industries. The community is praising AMD's robust product pipeline and strategic partnerships, seeing the company as a credible and substantive leader in the evolving AI and high-performance computing landscape.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant attention due to its GPS immunotherapy, with community discussion centered on the unexpected longevity of patients in its ongoing AML trial, signaling strong efficacy and a potential paradigm shift in cancer treatment. Investors are actively debating a substantial revaluation and the strong likelihood of a competitive buyout, fueled by the drug's promising performance and a belief that short positions are increasingly vulnerable amidst high borrow fees and limited share availability.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending with strong community engagement, largely fueled by a vibrant ecosystem of memecoins, notably $WEEDCOIN, which are driving significant conversation and perceived liquidity. Users are actively discussing Solana's price potential and its role in an anticipated altcoin market expansion, often highlighting its efficiency as a layer-one network.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after its CES keynote introduced the Vera Rubin AI platform, now in full production, and emphasized its strategy to deliver complete AI supercomputer stacks, accelerating the push into physical AI, robotics, and autonomous vehicles. The community is buzzing with excitement over these future-forward initiatives and NVIDIA's continued innovation, though some investors debate whether current market valuations fully reflect these long-term growth prospects.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as market sentiment weighs the impact of increased competition from a recently launched oral GLP-1, sparking concerns over pricing and market share in the obesity space. Despite the pressure, the community remains divided, with many emphasizing VKTX's robust clinical data and upcoming catalysts like the J.P. Morgan Conference and potential FDA updates on its oral program. Optimism persists for a potential strategic partnership or acquisition, fueling ongoing debates around executive stock sales and the company's long-term value in a rapidly evolving market.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is trending due to community excitement surrounding political tailwinds, particularly discussions about cannabis rescheduling and potential tax reform, which are seen as catalysts for fundamental growth. The community actively promotes WEEDCOIN as the 'Green Wave' and a significant liquidity driver within the Solana ecosystem, advocating for biological sovereignty and challenging traditional pharmaceutical narratives. Holders emphasize long-term commitment and cultural alignment, rallying under the slogan 'Like Bitcoin But Way Higher'.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Zenas Biopharma Inc.

Zenas BioPharma is trending after its Phase 3 trial results for obexelimab, which, despite meeting primary endpoints, triggered a substantial stock decline. The market's sharp reaction appears driven by perceptions of the drug's efficacy falling short of competitor treatments and the impact on milestone payments. This has ignited community debate, with many viewing the stock as deeply oversold and a potential bounce play against significant short interest.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is a hot topic amidst widespread community discussions about an "altcoin season" and general crypto market growth, propelled by hopes for the "Clarity Act" and potential future rate adjustments. The conversation centers on its technical developments like LitVM and Drivechains, paired with diminishing supply, contrasting with debates about its performance compared to other major cryptocurrencies.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending following its strategic collaboration with OpenAI to power its Athena marketing platform, sparking immense community enthusiasm and a surge in trading volume. Many market participants view ZETA as significantly undervalued for an AI-leveraged Martech company, anticipating a substantial re-rating and further catalysts as it approaches CES 2026.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is surging following news of its 4D LiDAR being selected for integration into the NVIDIA DRIVE Hyperion Platform, sparking widespread community excitement. Investors are bullish, anticipating a significant short squeeze due to high short interest, with many eyeing substantial price targets. This strategic partnership firmly positions the LiDAR innovator at the center of autonomous driving and physical AI discussions, despite some caution regarding long-term revenue timelines.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Equity

Best Healthcare Stocks To Consider - January 5th

UnitedHealth Group, Johnson & Johnson, Hims & Hers Health, McKesson, Intuitive Surgical, HCA Healthcare, and Tempus AI are the seven Healthcare stocks to watch today, according to MarketBeat's stock...

Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization

HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.

Promising Healthcare Stocks To Keep An Eye On - January 4th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Medtronic, Hims & Hers Health, Ironwood Pharmaceuticals, and Tempus AI are the seven Healthcare stocks to watch today, according to...

Promising Healthcare Stocks To Consider - January 3rd

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Medtronic, and Hims & Hers Health are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare...

Best Healthcare Stocks To Watch Now - January 2nd

UnitedHealth Group, Johnson & Johnson, Ironwood Pharmaceuticals, Intuitive Surgical, Medtronic, Hims & Hers Health, and Tempus AI are the seven Healthcare stocks to watch today, according to...

Healthcare Stocks To Consider - January 1st

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Hims & Hers Health, and Medtronic are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare...

Healthcare Stocks To Watch Today - December 31st

UnitedHealth Group, Johnson & Johnson, Hims & Hers Health, Molina Healthcare, Intuitive Surgical, Tempus AI, and Medtronic are the seven Healthcare stocks to watch today, according to MarketBeat's...

Unpacking the Latest Options Trading Trends in Hims & Hers Health

Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $33.05, representing a -3.09% change from its previous close.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$34.71
Prev Close	$33.41
Open	$33.96
Dividend Yield	0.00%
50-Day Moving Average	$38.62
Beta	2.11
Avg. Volume	12.42M
PE Ratio	64.17

52-Week High	$72.98
52-Week Low	$23.97
Market Capitalization	$7.61B
EPS (Annual)	$0.5322
Price to Book	13.59
Revenue Per Employee	$901,963.35
Enterprise Value/EBITDA	N/A

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMSHims & Hers Health Inc